Skip to content

    Glenmark Pharma.

    GLENMARK
    Healthcare·26 May 2025
    Management Summary

    Glenmark Pharma reported a mixed Q4 FY25, with consolidated revenue growing 6.3% YoY to INR32,562 million and FY25 revenue up 12.8% to INR1,33,217 million. While Europe and ROW businesses showed strong performance, India formulation sales growth was muted at 0.4% due to market competition and strategic brand rationalization. North America revenue declined 5.4% in Q4, though an uptick is expected from FY26 with new launches. The company provided FY26 guidance of 10-12% revenue growth and 19-20% EBITDA margin.

    Highlights

    5
    • FY25 Consolidated Revenue grew 12.8% YoY to INR1,33,217 million.

    • Q4 FY25 Consolidated Revenue increased 6.3% YoY to INR32,562 million.

    • Europe business grew close to 18% for the full year FY25, contributing 21.4% to consolidated revenues.

    • RYALTRIS is now commercialized in 45+ markets globally and is expected to reach $100 million in global sales for FY26.

    • Aurangabad plant was inspected in September 2024 and received 0 observations.

    Concerns

    3
    • North America Q4 revenue declined 5.4% YoY to INR7,146 million due to lack of meaningful launches.

    • India formulation business Q4 sales grew only 0.4% YoY to INR9,430 million, impacted by weak respiratory market and competitive diabetes market (10% decline for Glenmark).

    • Exceptional loss in Q4 associated with the closure of the La Chaux-de-Fonds manufacturing facility and generic Zetia litigation.

    What Changed2

    vs Q1 FY26

    Guidance items8 → 9 (+1)Risks discussed3 → 6 (+3)

    Key financials

    Single quarter

    06 metrics
    1. 01Consolidated Revenue Q432,562 Mn+6.3%YoY
    2. 02Consolidated Revenue FY251,33,217 Mn+12.8%YoY
    3. 03R&D Spend Q4₹236.7 Cr
    4. 04R&D Spend FY25₹930.5 Cr
    5. 05Adjusted PAT Q4₹346.6 Cr

    Segment breakdown

    Revenue Q4Contribution to Consol Revenue FY25
    India Formulation9,430 Mn33.7%
    North America7,146 Mn22.6%
    Europe7,335 Mn21.4%
    ROW7,898 Mn21.1%
    India Consumer Care (GCC)
    Heatmap· 2 shared metrics

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹489 crores

    M&A

    Humana, Centene, Kaiser (Zetia litigation settlement)

    Other · closed · Consideration ₹NaN (cash)

    M&A

    La Chaux-de-Fonds manufacturing facility

    divestment · closed

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    Revenue Growth
    10% to 12%
    High
    Margin
    EBITDA Margin
    19% to 20%
    High
    Cash Flow
    Cash Generation
    INR300 crores to INR400 crores
    High
    R&D Spend
    R&D Expenditure as % of Sales
    6% to 7%
    Medium
    Product Launch
    WINLEVI Launch in UK
    Launch
    High
    Product Launch
    Tislelizumab plus Zanubrutinib Launch in India
    Launch
    High
    Product Approval
    Generic Flovent 44 MCG Approval
    Approval
    Medium
    Tax Rate
    Tax Rate
    21% to 22%
    High

    ISB 2001 Licensing Deal Closure

    next quarter
    CurrentIn advanced discussions with multiple big pharma partners.
    TargetDeal closure / announcement.

    Why it matters

    A transformational deal expected to fund IGI for 3-4 years and significantly improve Glenmark's margins.

    I think you should see some visibility around a licensing deal pretty quickly. That's the only comment I can make as far as 2001 goes.

    How to verify

    capital_allocation.m_and_a[target='ISB 2001 deal'].status

    Risks & concerns

    6
    RiskSeverity

    US Executive Order impact on brand pharma

    Executive order towards most favored nation clause could impact brand pharma more than generics.Analyst acknowledged

    medium

    India diabetes market competition and portfolio transition

    Highly competitive diabetes market led to 10% decline in Q4; transition to new products is ongoing.Both acknowledged

    medium

    North America revenue decline due to lack of launches

    Q4 FY25 North America revenue declined 5.4% due to lack of meaningful launches, though an uptick is expected from FY26.Management acknowledged

    medium

    Flovent development and approval slippage

    Flovent is an 'extremely difficult product' and approval for 44 strength is expected towards end of Q2 FY26 with 'some slippage'.Both acknowledged

    medium

    Pithampur plant FDA resolution uncertainty

    Discussions with FDA ongoing for Pithampur, but management states minimal commercial impact as no launches are from there.Both downplayed

    medium

    Working capital elongation

    Net working capital days at 104, aligned with global peers but higher than previous year.Analyst acknowledged

    low

    Q&A highlights

    8

    “Well, I think the -- I mean, given the executive order towards the most favored nation clause, I think there's still -- clarity still needs to evolve on that whole thing. But our view internally is that the major impact will be for brand pharma as compared to generics.”

    Addresses a macro regulatory risk and clarifies management's view on its impact on different pharma segments.

    asked by Harshit Dhoot

    2 min read6 chapters

    Detailed Narrative

    01

    Overall Financial Performance and FY26 Outlook

    Glenmark Pharmaceuticals reported a consolidated revenue of INR32,562 million for Q4 FY25, marking a 6.3% year-over-year growth. For the full fiscal year 2025, consolidated revenue reached INR1,33,217 million, growing 12.8% YoY. The company provided an optimistic outlook for FY26, guiding for 10-12% revenue growth, an EBITDA margin of 19-20%, and cash generation between INR300-400 crores, primarily driven by core business performance.

    02

    Regional Performance Highlights

    Europe demonstrated strong performance, growing nearly 20% in Q4 FY25 to INR7,335 million and contributing 21.4% to FY25 consolidated revenues, driven by its branded business. The ROW region also saw a 4.9% growth in Q4 to INR7,898 million, with strong contributions from Russia (10.2% secondary sales growth) and LatAm. North America, however, experienced a 5.4% decline in Q4 revenue to INR7,146 million due to a lack of significant new launches, though an uptick is anticipated from FY26 with upcoming respiratory and injectable product launches.

    03

    India Business Challenges and Strategic Shifts

    India's formulation business recorded a modest 0.4% YoY growth in Q4 FY25, reaching INR9,430 million. This was primarily attributed to a weak acute respiratory market, intense competition in the diabetes segment leading to a 10% decline for Glenmark, and the strategic discontinuation of certain low-margin brands. To counter this, Glenmark is transitioning its diabetes portfolio from older molecules to newer ones like Lirafit, sitagliptin, and empagliflozin, with semaglutide launch planned, aiming to stabilize and grow the franchise.

    04

    Specialty and Innovation Pipeline Progress

    Glenmark's specialty product RYALTRIS continues to perform well, now commercialized in over 45 markets globally, with an expected global sales target of $100 million for FY26. WINLEVI received approval from the U.K. MHRA in Q4 FY25, with a launch planned for FY26. The innovation entity, IGI, made significant progress with its lead asset ISB 2001, receiving Fast Track designation from the U.S. FDA in May 2025 and completing Phase I dose escalation, with further data to be presented at ASCO.

    05

    Manufacturing and Regulatory Updates

    The Aurangabad plant underwent an inspection in September 2024 with zero observations, indicating strong compliance. However, the Pithampur plant's regulatory status remains under discussion with the FDA, though management noted minimal commercial impact. IGI announced the cessation of manufacturing at its La Chaux-de-Fonds facility in Switzerland, transferring activities to CDMOs to support higher volumes for future clinical programs, which also contributed to an exceptional loss in Q4.

    06

    Capital Allocation and Debt Management

    Total asset additions for FY25 amounted to INR698 crores, with Q4 additions at INR309 crores. Net debt as of March 2025 stood at approximately INR489 crores. The company's working capital days were reported at 104, aligning with global peers. Interest expense in Q4 was INR66 crores, with a slight increase due to higher debt, but is expected to be lower in the coming year. The FY26 tax rate is projected to be 21-22%.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.